

**STINGRAY HEALTHCARE CONTINUES ITS DEVELOPMENT IN FRANCE  
THROUGH A PARTNERSHIP WITH ONCOGARD IN NÎMES**

**18.11.2022** – Stingray Healthcare (“Stingray”, formerly known as MedEuropa Group), an alliance of medical professionals, healthcare managers and entrepreneurs committed to the support and development of cancer care practices, has finalised a partnership with Oncogard’s shareholding doctors in Nîmes to support the long-term provision of cancer care in the region.

As the only private radiotherapy centre in the Gard region of France, Oncogard provides high-quality treatments to over 1,100 patients per year in Nîmes and the surrounding area. In addition, Oncogard offers oncology consultations and chemotherapy treatments at its main site in Nîmes as well as a second site at the public hospital in Alès. Oncogard’s medical team has continuously improved the quality of patient care through investment in modern radiotherapy equipment and the application of a multidisciplinary approach, supporting the provision of innovative and personalised treatments.

*“The partnership with Stingray strengthens the future development of our centre in a model that allows us doctors to remain involved in the strategic decisions over the long term”* says Eric Legouffe, shareholding doctor and managing director at Oncogard.

The Stingray team is particularly enthusiastic about partnering with a *“medical team that has been recognised for years for its excellent reputation in the Gard, and beyond”* as Ralph Hefti, CEO of Stingray, remarks.

The partnership with Oncogard, by way of a majority stake acquisition, expands Stingray’s presence in France, where the Group has been active for three years, concluding similar partnerships with leading physicians in Perpignan and Dunkirk.

Stingray has the ambition to become the independent European leader in radiotherapy and is therefore continuously looking for new partnerships with leading medical teams, particularly in France and Germany.

**Contact**

Ralph Hefti, CEO

[ralph.hefti@stingray-healthcare.com](mailto:ralph.hefti@stingray-healthcare.com)

### **About Oncogard**

Oncogard is the only private provider of cancer care in the Gard region (South of France). It operates one radiotherapy and two consultation and chemotherapy sites in Nîmes and Alès. Over 50 oncology professionals collaborate to provide advanced cancer care services to over 1,100 patients every year. The centre is equipped with the latest technology and, through a health co-operation consortium, works closely with the Centre Hospitalier Universitaire de Nîmes and Unicancer's Institut du Cancer de Montpellier.

Please visit [www.oncogard.fr](http://www.oncogard.fr) for more information.

### **About Stingray Healthcare**

Stingray (formerly known as MedEuropa Group) was founded in 2017 to support the fight against cancer by ensuring the long-term success of treatment centres across Europe.

Today, Stingray supports more than 200 highly committed medical professionals treating over 8,000 patients per year in radiotherapy and radiosurgery centres in Germany and France. The company teams up with cancer care professionals in a distinctive partnership model, bringing a range of complementary resources to bear, including capital and strategic expertise.

The Swiss-headquartered company is supported by family capital, with significant ownership held by its doctors and senior management team.

Please visit [www.stringray-healthcare.com](http://www.stringray-healthcare.com) for more information.

### **About Telemos Capital**

Telemos comprises a team of highly experienced investment professionals that combine the best of private equity and permanent capital. Founded in 2017, Telemos identifies and supports exceptional management teams in consumer goods, healthcare services, and business services to help them realise their long-term objectives. As a flexible and nimble investor, Telemos' distinct structure and expertise make it a leading, new generation European private equity firm, looking to identify and unlock attractive opportunities for growth and value creation.

Please visit [www.telemoscapital.com](http://www.telemoscapital.com) for more information.